IntelliCell BioSciences, Inc. Announces Name Change From Media Exchange Group, Inc. & New Trading Symbol “SVFC”
IntelliCell BioSciences, Inc. Announces Name Change From Media Exchange Group, Inc. and New Trading Symbol “SVFC”
NEW YORK, NY–(July 7, 2011 07:00 ET) – IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) and formerly (OTCQB: CWLC) (PINKSHEETS: CWLC) (“IntelliCell” or the “Company”), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, today announced that it has changed its name from Media Exchange Group, Inc. to IntelliCell BioSciences, Inc., effective June 27, 2011. In connection with this name change to IntelliCell BioSciences, Inc., as of the open of trading on July 7, 2011, the Company’s new trading symbol on the OTCQB will be “SVFC.” The purpose of the name change is to better reflect the Company’s business operations.
Dr. Sarah Carroll, Chairman and Chief Executive Officer of the Company, commented, “We are pleased to move forward under our new ticker and corporate name. Our new corporate name enables us to communicate more effectively with our customers and partners in the growing regenerative medical industry.”
About IntelliCell Biosciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled “autologous homologous.” IntelliCell has already established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit https://www.intellicellbiosciences.com or call 212 1329875.
Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.